Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
30
JANX Quote, Financials, Valuation and Earnings
Last price:
$13.59
Seasonality move
:
-11.9%
Day range:
$13.71 - $14.14
52-week range:
$12.12 - $35.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
84.15x
P/B ratio:
0.86x
Volume:
1.1M
Avg. volume:
1M
1-year change:
-51.86%
Market cap:
$826.1M
Revenue:
$10M
EPS (TTM):
-$1.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$76.9K | -$0.64 | 599.64% | -47.86% | $54.00 |
|
BMY
Bristol Myers Squibb Co.
|
$12.3B | $1.20 | -2.96% | 20.33% | $62.36 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 167.16% | 10.26% | $14.57 |
|
EYPT
EyePoint Plc
|
$1M | -$0.75 | -98.65% | -25.43% | $37.42 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$312.7M | -$0.88 | 119.49% | -25.18% | $667.57 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.93% | -59.34% | $7.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
$13.58 | $54.00 | $826.1M | -- | $0.00 | 0% | 84.15x |
|
BMY
Bristol Myers Squibb Co.
|
$59.08 | $62.36 | $120.3B | 17.08x | $0.63 | 4.22% | 2.50x |
|
CRMD
CorMedix, Inc.
|
$6.45 | $14.57 | $509.9M | 3.25x | $0.00 | 0% | 1.66x |
|
EYPT
EyePoint Plc
|
$13.20 | $37.42 | $1.1B | -- | $0.00 | 0% | 30.81x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$444.83 | $667.57 | $10.1B | -- | $0.00 | 0% | 10.40x |
|
MNKD
MannKind Corp.
|
$2.77 | $7.50 | $853.4M | 164.88x | $0.00 | 0% | 2.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
2.26% | 0.189 | 2.66% | 38.67x |
|
BMY
Bristol Myers Squibb Co.
|
71.85% | -0.653 | 44.08% | 0.88x |
|
CRMD
CorMedix, Inc.
|
26.87% | 2.923 | 16.15% | 1.84x |
|
EYPT
EyePoint Plc
|
6.93% | 1.265 | 1.51% | 8.28x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
36.58% | -0.182 | 2.63% | 3.62x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.12% | 1.23x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics, Inc.
|
-$468K | -$42.4M | -11.2% | -11.46% | -352.51% | -$28.6M |
|
BMY
Bristol Myers Squibb Co.
|
$8.3B | $3.6B | 10.38% | 39.9% | 29.05% | $1.6B |
|
CRMD
CorMedix, Inc.
|
$107.3M | $59.1M | 60.2% | 67.96% | 45.97% | $92.7M |
|
EYPT
EyePoint Plc
|
-$104K | -$70.3M | -77.2% | -83.61% | -11345.97% | -$66M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$296.2M | -$59.6M | -32.42% | -42.53% | -18.57% | -$133.1M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
Janux Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns JANX or BMY?
Bristol Myers Squibb Co. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 8.69%. Janux Therapeutics, Inc.'s return on equity of -11.46% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.51 $979M BMYBristol Myers Squibb Co.66.24% $0.53 $65.6B -
What do Analysts Say About JANX or BMY?
Janux Therapeutics, Inc. has a consensus price target of $54.00, signalling upside risk potential of 297.64%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $62.36 which suggests that it could grow by 5.55%. Given that Janux Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Janux Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.13 1 0 BMYBristol Myers Squibb Co.6 18 1 -
Is JANX or BMY More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.265, suggesting its less volatile than the S&P 500 by 73.533%.
-
Which is a Better Dividend Stock JANX or BMY?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.22% to investors and pays a quarterly dividend of $0.63 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JANX or BMY?
Janux Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Janux Therapeutics, Inc.'s net income of -$31.9M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 84.15x versus 2.50x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.84.15x -- -- -$31.9M BMYBristol Myers Squibb Co.2.50x 17.08x $12.5B $1.1B
-
Which has Higher Returns JANX or CRMD?
CorMedix, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 10.9%. Janux Therapeutics, Inc.'s return on equity of -11.46% beat CorMedix, Inc.'s return on equity of 67.96%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.51 $979M CRMDCorMedix, Inc.83.43% $0.15 $554.2M -
What do Analysts Say About JANX or CRMD?
Janux Therapeutics, Inc. has a consensus price target of $54.00, signalling upside risk potential of 297.64%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.57 which suggests that it could grow by 125.91%. Given that Janux Therapeutics, Inc. has higher upside potential than CorMedix, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.13 1 0 CRMDCorMedix, Inc.4 0 0 -
Is JANX or CRMD More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.308, suggesting its more volatile than the S&P 500 by 30.754%.
-
Which is a Better Dividend Stock JANX or CRMD?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or CRMD?
Janux Therapeutics, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $128.6M. Janux Therapeutics, Inc.'s net income of -$31.9M is lower than CorMedix, Inc.'s net income of $14M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 84.15x versus 1.66x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.84.15x -- -- -$31.9M CRMDCorMedix, Inc.1.66x 3.25x $128.6M $14M
-
Which has Higher Returns JANX or EYPT?
EyePoint Plc has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -10904.68%. Janux Therapeutics, Inc.'s return on equity of -11.46% beat EyePoint Plc's return on equity of -83.61%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.51 $979M EYPTEyePoint Plc-16.77% -$0.81 $328.9M -
What do Analysts Say About JANX or EYPT?
Janux Therapeutics, Inc. has a consensus price target of $54.00, signalling upside risk potential of 297.64%. On the other hand EyePoint Plc has an analysts' consensus of $37.42 which suggests that it could grow by 183.46%. Given that Janux Therapeutics, Inc. has higher upside potential than EyePoint Plc, analysts believe Janux Therapeutics, Inc. is more attractive than EyePoint Plc.
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.13 1 0 EYPTEyePoint Plc10 0 0 -
Is JANX or EYPT More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.725, suggesting its more volatile than the S&P 500 by 72.48%.
-
Which is a Better Dividend Stock JANX or EYPT?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or EYPT?
Janux Therapeutics, Inc. quarterly revenues are --, which are smaller than EyePoint Plc quarterly revenues of $620K. Janux Therapeutics, Inc.'s net income of -$31.9M is higher than EyePoint Plc's net income of -$67.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 84.15x versus 30.81x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.84.15x -- -- -$31.9M EYPTEyePoint Plc30.81x -- $620K -$67.6M
-
Which has Higher Returns JANX or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -18.24%. Janux Therapeutics, Inc.'s return on equity of -11.46% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.51 $979M MDGLMadrigal Pharmaceuticals, Inc.92.26% -$2.57 $950.3M -
What do Analysts Say About JANX or MDGL?
Janux Therapeutics, Inc. has a consensus price target of $54.00, signalling upside risk potential of 297.64%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $667.57 which suggests that it could grow by 50.07%. Given that Janux Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.13 1 0 MDGLMadrigal Pharmaceuticals, Inc.11 2 0 -
Is JANX or MDGL More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.970, suggesting its less volatile than the S&P 500 by 196.976%.
-
Which is a Better Dividend Stock JANX or MDGL?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or MDGL?
Janux Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Janux Therapeutics, Inc.'s net income of -$31.9M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 84.15x versus 10.40x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.84.15x -- -- -$31.9M MDGLMadrigal Pharmaceuticals, Inc.10.40x -- $321.1M -$58.6M
-
Which has Higher Returns JANX or MNKD?
MannKind Corp. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -14.25%. Janux Therapeutics, Inc.'s return on equity of -11.46% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JANXJanux Therapeutics, Inc.94.99% -$0.51 $979M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About JANX or MNKD?
Janux Therapeutics, Inc. has a consensus price target of $54.00, signalling upside risk potential of 297.64%. On the other hand MannKind Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 170.76%. Given that Janux Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Janux Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings JANXJanux Therapeutics, Inc.13 1 0 MNKDMannKind Corp.8 1 0 -
Is JANX or MNKD More Risky?
Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock JANX or MNKD?
Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JANX or MNKD?
Janux Therapeutics, Inc. quarterly revenues are --, which are smaller than MannKind Corp. quarterly revenues of $112M. Janux Therapeutics, Inc.'s net income of -$31.9M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 164.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 84.15x versus 2.48x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JANXJanux Therapeutics, Inc.84.15x -- -- -$31.9M MNKDMannKind Corp.2.48x 164.88x $112M -$15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
